Chimeric Animal Inflammation Prevention Technology

The original patent disclosed a method for obtaining an adult individual from a xenogeneic or allogeneic chimeric animal fetus individual, but it had limitations in addressing immune response and inflammation after birth. The present invention addresses these limitations by introducing a monitoring module, controlled release composition, and sensor-enabled device to prevent and treat inflammation in chimeric animals more effectively.

The present invention introduces novel elements, such as the monitoring module, controlled release composition, and sensor-enabled device, which are not present in the original patent. These elements provide an inventive step by enabling more efficient, safer, and targeted treatment of inflammation in chimeric animals.

Alternative embodiments of the invention could include varying the type of anti-inflammatory agent or immunosuppressive agent used, adjusting the controlled release mechanism, or integrating the system with other medical devices. Variations could also involve adapting the invention for use in different species or for treating different types of inflammation.

The invention has significant commercial potential in the fields of regenerative medicine, biotechnology, and veterinary care. It could be used to improve the health and well-being of chimeric animals, enabling the development of new therapies and treatments. The target market includes research institutions, biotech companies, and veterinary clinics.